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Abstract:  In  this  study,  vascular  stents  were  fabricated  from  poly  (lactide-ʵ-
caprolactone)/collagen/nano-hydroxyapatite (PLCL/Col/nHA) by electrospinning, and the 
surface morphology and breaking strength were observed or measured through scanning 
electron microscopy and tensile tests. The anti-clotting properties of stents were evaluated 
for  anticoagulation  surfaces  modified  by  the  electrostatic  layer-by-layer  self-assembly 
technique. In addition, nano-composite scaffolds of poly (lactic-co-glycolic acid)/polycapr-
olactone/nano-hydroxyapatite  (PLGA/PCL/nHA)  loaded  with  the  vascular  stents  were 
prepared by thermoforming-particle leaching and their basic performance and osteogenesis 
were  tested  in  vitro  and  in  vivo.  The  results  show  that  the  PLCL/Col/nHA  stents  and 
PLGA/PCL/nHA  nano-composite  scaffolds  had  good  surface  structures,  mechanical 
properties,  biocompatibility  and  could  guide  bone  regeneration.  These  may  provide  a  
new way to build vascularized-tissue engineered bone to repair large bone defects in bone  
tissue engineering. 
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Bone tissue engineering has provided a new way to repair, restore or regenerate large bone defects 
impaired by disease, injury, or age [1]. Constructs are typically created by seeding a scaffold with cells 
in  vitro.  Scaffolds  are  an  important  component  in  bone  tissue  engineering  and  these  should  be  
three-dimensional, with a highly porous network of interconnected pores that can promote cell growth, 
adhesion,  proliferation  and  differentiation  by  facilitating  the  flow  and  transport  of  nutrients  and 
metabolic waste. In addition, they should have good biocompatibility and biodegradability to ensure 
they are non-toxic, non-allergic and cause no other adverse reactions to cells and the body and promote 
the formation of new tissues matched to the degradation rate of stent materials. Furthermore, they 
should have good biological activity to improve cell viability and promote tissue regeneration. Finally, 
good  mechanical  properties  are  also  essential  requirements  of  an  ideal  scaffold  in  bone  tissue 
engineering [2–5]. Currently, vascularization has been the greatest problem in the successful repair of 
large  bone  defects  by  bone  tissue  engineering  [1,6].  Therefore,  the  construction  and  mechanical, 
biological and anti-clotting properties of scaffolds are of crucial importance. 
The normal vascular anatomy, in addition to capillaries and lymphatic capillaries, includes an outer 
membrane,  a  membrane  and  intimal  layers. Endometrial  lining  is  constituted by a  single  layer of 
epithelial cells in the basement membrane, and presents a smooth surface, rich in various types of 
collagen and elastin. The membrane is the thickest layer, with good mechanical properties, composed 
of  smooth  muscle  cells  arranged  in  layers  of  interaction.  The  adventitia  is  composed  of  loose 
connective tissue, which mainly contains fibroblast and type I collagen [7]. Ideal vascular stents should 
have the following characteristics: (1) they simulate the structure of normal vascular anatomy; (2) they 
have good biocompatibility and biological characteristics; (3) they have sufficient mechanical properties 
and compliance [8–10]. 
Currently,  electrospinning  has  been  the  main  method  for  tissue  engineering  of  stents  in  many  
nano-fiber preparation technologies [11,12]. It has the following major advantages: (1) electrospun 
fiber stents have good biocompatibility; (2) precursor solutions of electrospinning are diverse; (3) the 
electrospinning process is highly controllable [13]. Nano-fibrous tissue engineered blood vessel stents 
have special advantages, as they are not only able to simulate the anatomy of the normal vascular 
tissue, but can mimic the composition and structure of the extracellular matrix to provide an ideal 
growing environment for cells, which are important prerequisites for the regeneration and reconstruction 
of blood vessels. In previous studies, tissue engineering of vascular stents could not fully be taken 
advantage of because implanting them into the body was prone to rapid thrombopoiesis, which is one 
of the limiting factors in clinical applications. To overcome this shortcoming, various methods for 
surface  modification  and  functional  modification  on  the  stent  surface  exist  that  can  improve 
performance by loading the surface with anti-clotting substances [14,15]. Layer-by-layer assembly has 
been one of the common means of modifying the stent surface in tissue engineering, which is not only 
suitable for materials with a variety of complex structures but also can fix a variety of biological 
molecules on the surface [16].  
Collagen is the most abundant protein in the human body and a key element of the extracellular 
matrix (ECM) which imparts structural integrity and tensile strength to tissues. Recently, it has been 
used in a lot of tissue engineering applications as its predominance in the ECM, non-immunogenicity Int. J. Mol. Sci. 2012, 13  3368 
 
 
and available methods of isolation from a variety of sources. In addition, collagen ﬁbers also possess 
some  unique  structural  properties  important  for  tissue  engineering:  they  transmit  forces,  dissipate 
energy,  prevent  premature  mechanical  failure and  provide  biological  signals  to  adjacent  cells  that 
regulate functional responses [17]. Collagen is resorbable, has high hydrophilicity, low antigenicity, 
very good biocompatibility and can promote tissue regeneration [18]. As it has many advantages, it has 
been one of the most ideal biopolymers available for tissue engineering applications. 
Biodegradable  polyesters,  such  as  polylactic  acid  (PLA),  polyglycolic  acid  (PGA)  and  their 
copolymers poly (lactic-co-glycolic acid) (PLGA), have good biocompatibility and biodegradation and 
are approved as a class of biological materials by the United States Food and Drug Administration 
(FDA). These show good mechanical strength, elastic modulus and can be thermally formed, so meet 
the  basic  requirements  of  carrier  materials  in  bone  and  cartilage  tissue  engineering  [19–21].  The 
mechanical properties and degradation rate of PLGA/PCL composite scaffolds can be improved by 
adjusting the molecular weight, structure and composition to meet different clinical requirements, and 
their ultimate degradation products are CO2 and H2O. Intermediate products of lactic acid are also the 
body’s normal sugar, so PLGA/PCL scaffold degradation in vivo will not have adverse effects on the 
organism [19,22,23]. In addition, excellent performances of composite materials have been widely 
reported  in  recent  years  [3,24].  The  introduction  of  inorganic  materials  such  as  hydroxyapatite, 
calcium silicate not only enhance the mechanical strength of scaffold materials but can neutralize the 
acid produced by polymer degradation to maintain a stable pH value [25,26]. Synthetic hydroxyapatite, 
a type of inorganic material, has been extensively studied and applied, and is similar to natural bone. It 
has  good  biocompatibility,  bioactivity  and  bone  leading  properties,  and  can  guide  new  bone 
regeneration from the host bone along implant interfaces or internal implants to form a good bone 
combination [27–30]. 
In this study, electrospinning technology was applied to prepare small, biomimetic vascular stents 
of poly (lactide-ʵ-caprolactone)/collagen/nano-hydroxyapatite (PLCL/Col/nHA), and a modified layer 
of  anti-coagulant  which  was  built  on  the  surface  to  improve  the  anti-clotting  properties  through  
layer-by-layer  assembly  technology.  New  nano-composite  scaffolds  loaded  with  vascular  stents 
prepared  by  tissue  engineering  technology  were  used  as  substitutes  for  bone  matrices,  with  good 
biocompatibility and mechanical properties. 
2. Results and Discussion 
2.1. Construction and Properties of Vascular Stents 
The  surface  morphology  of  the  vascular  stents  was  observed  by  scanning  electron  microscopy 
(SEM) (Figure 1), exhibiting a highly uniform thickness and ordered arrangement of nano-fibers. Each 
group of components and concentration is shown in Table 1. The concentration of solution greatly 
affected the morphology and diameter of electrospun fibers and had to exceed a critical value of 
electrospinning  to  carry  out  the  process  of  electrostatic  spinning  smoothly.  When  the  solution  is 
diluted, it cannot form a stable fluid and will directly contract under the effects of surface tension and 
form  liquid  beads  or  silk.  Mutual  entanglement  of  polymer  chains  with  increasing  concentration 
prevents the deformation of small streams, forming uniform fibers, but if the concentration continues Int. J. Mol. Sci. 2012, 13  3369 
 
 
to increase, the solution will be gelatinous and not conducive to formation of neat fibers [31]. In this 
study,  the  viscosity  of  the  spinning  solution  increased  significantly  with  increasing  PLCL 
concentration.  nHA  had  less  influence  on  the  fiber  diameter  than  collagen  at  low  content.  0.3% 
collagen could make the stents exhibit better hydrophilicity and biocompatibility compared with 0.2%, 
0.4% and 0.5%, which had been studied and proved by comparative pre-studies. 
Figure 1. Scanning Electron Microscopy (SEM) images of different vascular stents: (a) poly 
(lactide-ʵ-caprolactone)  (PLCL)  group;  (b)  PLCL/nano-hydroxyapatite  (nHA)  group;  
(c) PLCL/collagen (Col)/nHA I group; (d) PLCL/Col/nHA II group. 
 
Table 1. The components of each group. 
Group  Components 
PLCL  PLCL, 10% (g/mL) 
PLCL/nHA  PLCL, 10% (g/mL) + nHA, 0.03% (g/mL) 
PLCL/Col/nHA I  PLCL, 10% (g/mL) + Col, 0.3% (g/mL) + nHA, 0.03% (g/mL) 
PLCL/Col/nHA II  PLCL + Col + nHA, 0.07% (g/mL), PLCL/Col = 1:2 (g/g) 
Compared with pure PLCL, the tensile strength of stents was improved slightly with the joining of 
nHA (p > 0.05) but it was significantly reduced through addition of collagen (p < 0.05) (Figure 2A). 
The break elongation ratio showed little change in PLCL/nHA group and PLCL/Col/nHA I group 
compared with pure PLCL group (p > 0.05). When the collagen content of scaffolds was higher than 
the  PLCL  content,  both  the  tensile  strength  and  breaking  elongation  ratio  were  greatly  reduced  
(p < 0.01) (Figure 2B). 
In this experiment, the clotting time of the pure PLCL fiber membrane was about 350 s, while the 
PLCL/Col/nHA  II  fiber  membrane  modified  through  the  electrostatic  self-assembly  technology 
showed a clotting time far greater than 1800 s (Figure 3) (all p values compared with control group are 
less than 0.05). Regardless of whether the outermost modified layers were chitosan (CTS) or heparin 
sodium (HS), all showed good anticoagulant properties, which may have resulted from the existence of 
a certain amount of HS on the fiber membrane surfaces, interspersed with the outermost layer. HS has Int. J. Mol. Sci. 2012, 13  3370 
 
 
good anticoagulant performance so membranes showed a corresponding improvement in performance 
with increasing HS. 
Figure 2. The mechanical properties of different vascular stents evaluated through tensile 





Figure 3. The anticoagulant properties of the stents assessed through recalcification time. 
 Int. J. Mol. Sci. 2012, 13  3371 
 
 
2.2. Preparation and Characterization of New Nano-Composite Scaffolds Loaded with Vascular Stents 
The general appearance of nano-composite scaffolds is white, and porous, with a highly uniform 
thickness and rough texture (Figure 4A(a)). The small stents were embedded in the nano-composite 
scaffolds and can be viewed from the schematic diagram (Figure 4A(b) black arrows instruction), the 
diameter and thickness of which are about 1 mm and 100 µm. 
The nano-composite scaffolds showed a porous structure, with a highly uniform pore distribution. 
The pores were well-connected, as could be seen after the images were magnified in Figure 4B(a,b,c). 
The pore size was 220~300 μm. SEM images of the small stents embedded in the nano-composite 
scaffolds can be viewed in Figure 4B(d) (red arrows instruction). 
Figure 4. The surface morphology of nano-composite scaffolds observed by naked eye (A) 
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In  the  contact angle tests, the contact angle  of PLGA/PCL/nHA  group  slightly increased than 
PLGA/PCL group (all p values compared with no nHA are larger than 0.05) that may be due to  
nano-scale effect (Figure 5A). In water absorption experiments, the amount of water absorption by the 
nano-composite scaffolds (PLGA/PCL/nHA) exhibited rapid growth in the first 12 h, followed by a 
much lower growth rate (Figure 5B). 
Figure 5. Hydrophilic performance of nano-composite scaffolds assessed by contact angle 





The compressive strength of nano-composite scaffolds was higher than the control group, which 
could be seen from Figure 6, demonstrating that strength was increased significantly through addition 
of nHA (all p values compared with no nHA are less than 0.01). Int. J. Mol. Sci. 2012, 13  3373 
 
 
Figure 6. The compressive strength of nano-composite scaffolds. 
 
Degradation is an important factor in tissue engineering scaffolds and can impact significantly on 
cell growth, tissue regeneration and the host response. Therefore, the degradation rate of scaffolds 
should be synchronized with the cell growth rate. In this study, the pH of scaffolds all decreased with 
degradation time (Figure 7A), mainly because of the lactic acid produced during the degradation of 
PLGA and PCL. However, the pH of pure PLGA/PCL decreased more quickly than PLGA/PCL/nHA, 
perhaps as a result of the neutralization of nHA and lactic acid. Similarly, the weight losses of pure 
PLGA/PCL were also greater than for PLGA/PCL/nHA (Figure 7B). In addition, the early degradation 
rates of scaffolds were all relatively slow and accelerated rapidly after 60 h. These results indicate that 
the PLGA/PCL/nHA scaffolds are more suitable for cell growth and proliferation. 
Figure 7. The changes in pH and weight during the process of in vitro degradation of 
nano-composite scaffolds. A represents pH curves and B represents the weight loss curves. 
 
From Figure 8a,b, we could see a large number of living cells lived within the scaffolds and only a 
small amount of apoptosis. These results showed that the scaffolds possess good biocompatibility. Int. J. Mol. Sci. 2012, 13  3374 
 
 
From  Figure  9a–d,  it  could  see  that  scaffolds  co-cultured  with  BMSCs  after  7  days  showed 
degradation in some areas, while cells exhibited monolayer attachment on the surface of scaffolds. 
Hydroxyapatite crystals appeared on the surface and inner wall of the scaffolds. 
Figure  8.  The  cell  activity  of  bone  marrow  mesenchymal  stem  cells  (BMSCs)  which 
seeded on scaffolds of PLGA/PCL/nHA loaded with vascular stents for 7 days was tested 
by  DAPI  and  EB  staining  and  observed  through  fluorescence  microscopy:  blue  dots 
represent living cells (a) and dead cells were red (b). 
 
Figure 9. The changes in surface morphology of nano-composite scaffolds seeded with 
BMSCs after 7 days. SEM images of different magnifications: (a) × 50; (b) × 100; (c) × 200;  
(d) × 500. 
 
At 4 weeks after surgery, the shadow areas of low-density in bone defects of PLGA/PCL/nHA 
loaded with vascular stents group had little changes compared with BMSCs/PLGA/PCL/nHA loaded Int. J. Mol. Sci. 2012, 13  3375 
 
 
with vascular stents group, which only slightly increased in the edges of defect areas (as Figure 10 red 
frame instruction). After 8 weeks, increasing mineralization in the implants was observed, and group b 
mandibles  demonstrated  greater  new  bone  formation  than  the  other  group.  At  12  weeks  after 
implantation, the radio density in bone defects of b group had closed to the surrounding normal bones 
especially in the edges of bone defects areas. Although, in the middle of the bone defects, the density 
was not uniform, that has demonstrated successful bone regeneration. 
Figure 10. X-ray films of bone regeneration after 4, 8, 12 weeks of implanting operation.  
a,b represents PLGA/PCL/nHA loaded with vascular stents group and BMSCs/PLGA/PCL/ 
nHA  loaded  with  vascular  stents  group  respectively.  Note:  better  bone  formation  and 
earlier mineralization in group b than group a. 
 
3. Experimental Section 
3.1. Isolation and Culture of BMSCs 
New Zealand rabbits’ bone marrow mesenchymal stem cells (BMSCs) were isolated from the tibiae 
by bone marrow washing combined with density gradient centrifugation, suspended in Dulbecco’s 
Modified  Eagle  Medium  (DMEM)  with  10%  fetal  bovine  serum  (FBS)  (Gibco  BRL),  100  U/mL 
penicillin and 100 μg/mL streptomycin, and incubated at 37 ° C with 5% humid CO2. The procedure 
was carried out as the method described by Hu et al. [32]. Cells reached 80% confluence in 8~10 days 
and then were suspended for passage. Cells of passage 3 were used to seed on scaffolds and for 
experiments in vitro and in vivo. Media was changed every 3 days. 
3.2. Vascular Stent and Nano-Composite Scaffold Preparation 
Under room temperature, PLCL (Mw, 246524) was dissolved in hexafluoro isopropyl alcohol with 
magnetic  stirring.  Collagen  and  nHA  [33]  which  were  produced  by  institute  of  Nano-  and  
Bio-Polymeric Materials of School of Materials Science and Engineering in Tongji University were Int. J. Mol. Sci. 2012, 13  3376 
 
 
then added, with stirring to uniformity by magnetic stirrer and ultrasonication for 5 min. The above 
prepared solution was injected by a 20 mL syringe, fixed on a syringe pump. The metal needle of the 
syringe was connected to the anode of a high voltage power supply, the outer diameter of which was 
1.2 mm. The receiver was a motor or foil with a rotating shaft located about 17 cm from the needle. 
The flow rate was then set to 2 mL/h, the voltage controlled to about 17 kV and the speed of the motor 
at 500 rpm/min. After approximately 2.5 h of electrospinning, the tubular stents were prepared and 
dried for 24 h under vacuum at room temperature. 
In addition, PLGA and PCL (mass ratio 7:3) were dissolved in chloroform solution, with magnetic 
stirring for complete dissolution to a uniform polymer solution. nHA was added to the solution and 
dispersed evenly through ultrasonication. Sodium chloride particle sizes of 224~300 μm were obtained 
by a standard sieve and added to the above polymer solution, and stirred with a glass stirrer to form a 
uniform paste containing pore-forming agents and with a specific mobility. The paste mixture was then 
poured into the dish and a polymer film obtained after solvent evaporation, which was then dried in a 
vacuum oven and cut to appropriate sizes. The shredded polymer film and vascular stent (diameter of 
0.9 mm) were placed in a mold, then placed into a hot-press at 6~7 MPa pressure at 70 ° C for 3 min. 
Finally, the solution was tested with silver nitrate until no white precipitate was observed, and the 
vascular stent support rods were removed and dried. 
3.3. Characterization 
3.3.1. Morphology 
The  morphology  of  the  vascular  stents,  nano-composite  scaffolds  and  complexes  of  cells  and 
scaffolds were studied by SEM (Hitachi S-2360N). All specimens were fixed by 2.5% glutaraldehyde, 
dehydrated with graded ethanol, dried at the critical point and the surface coated with gold before  
SEM observation. 
3.3.2. Cell Activity 
The  cell  activity  of  bone  marrow  mesenchymal  stem  cells  (BMSCs)  which  were  seeded  onto 
scaffolds of PLGA/PCL/nHA loaded with vascular stents for 7 days was tested by DAPI and EB 
staining. The samples of scaffolds seeded BMSCs were added 100 μL DAPI and EB staining solution 
and incubated at 37 ° C for 15 min. Then fluorescence microscopy was used to observe the morphology 
of living and dead cells at the wavelength conditions of 490 nm and 545 nm respectively. The cell 
activity was tested by calculating the percentage of living cells of the total cells.  
3.3.3. Hydrophilic Performance 
The  hydrophilic  performances  of  nano-composite  scaffolds  were  measured  by  detection  of  the 
contact angle and water absorption ability. The samples were prepared as polymer films and contact 
angles were measured by the sessile drop method. In addition, specimens with dimensions 10 ×  10 ×  20 mm 
were dried and weighed as W1, then immersed and soaked in deionized water at 25 ° C. Subsequently, 
the specimens were removed from the water at specified times of 1, 2, 4, 8, 12, 24 and 48 h, the excess Int. J. Mol. Sci. 2012, 13  3377 
 
 
water on the surface of the scaffold was blotted with filter paper and the samples then weighed as W2. 
The water absorption ratio, a, of specimens at different times is defined as: 
a = (W2 − W1)/W1 ×  100%  (1)  
3.3.4. Mechanical Properties 
The tensile strength of vascular stents and the compressive strength of nano -composite scaffolds 
were evaluated using a computer controlled  tension tester  (TUV CMT6104) and pressure tester 
(DXLL-5000).  The  tension  tester  tested  the  tensile  strength  of  fiber  membrane  samples  with 
dimensions 80 × 10 mm, which represented the vascular stents. The effective distance was 20 mm and 
the test speed was 10 mm/min. In addition, the compressive strength of round, flaky specimens with 
dimensions  15 mm (diameter)  ×  3 mm (thickness) was evaluated according to the national test 
standards of China for compression of rigid cellular plastics (GB 8813-1988). The testing was carried 
out under the following conditions: room temperature, dry and a loading speed of 1 mm/min. 
Compressive strength was calculated as follows:  
˃c = P/A  (2)  
where ˃c represents the compressive strength; p is the load at 30% stent compression; and A is the 
cross-sectional area (mm
2). 
3.3.5. Anticoagulant Property 
(1) Solution configuration: Polyetherimide (PEI) solution, 1 mg/mL; HOAc-NaOAc buffer solution, 
pH 3.8; HS and CTS solution, 1 mg/mL; (2) Stent surface activation: Stents were immersed in PEI 
solution  for  10  min,  removed,  rinsed  with  distilled  water  and  dried;  (3)  Stent  anticoagulation 
modification: First, stents were immersed in HS solution for 20 min, removed, washed with distilled 
water and dried; then they were immersed in the CTS solution for 20 min and the above steps repeated 
10 times to modify alternately with heparin and chitosan in the outermost layer. Afterwards, fresh 
Ca
2+-depleted plasma, 0.025 mol/L CaCl2 and fiber membranes were placed into an incubator at 37 ° C 
for 10 min and then removed; 20 μL of the plasma and 20 μL of the CaCl2 solution were absorbed by 
pipette successively and dripped onto fiber membrane, while stirring the plasma with a small glass 
needle and recording the times of CaCl2 solution addition and production of filamentous fibers. The 
time of anti-clotting recalcification was measured by time interval. 
3.3.6. Degradability 
Specimens with a dimension of 8 mm (diameter) ×  2 mm (thickness) were accurately weighed and 
placed into numbered test tubes. Then 10 mL of PBS buffer solution were added to the tubes and they 
were placed into a constant temperature bath at 37 ° C. The phosphate buffered saline (PBS) buffer 
solution was changed once a day for the first two days and then changed weekly, and the pH value 
recorded with time. Corresponding samples were removed at 1, 2, 4, 7, 14, 21, 28, 35, 42, 49, 56, 63, 
and  70  days,  and  the  rate  of  weight  loss  of  the  scaffolds  and  the  changes  in  pH  measured  with 
degradation time.  Int. J. Mol. Sci. 2012, 13  3378 
 
 
3.3.7. Preparation of the Bone Defect Model and Implantation of Experimental Material 
Thirty healthy New Zealand white rabbits weighing about 2.5 kg each were divided into two groups: 
group a (n = 15): PLGA/PCL/nHA loaded with vascular stents group (served as control). Group b (n = 
15): BMSCs/PLGA/PCL/nHA loaded with vascular stents group. The rabbits were anesthetized with 
pentobarbital sodium (0.2 mL/kg). A 3 cm incision was made on the bilateral jaw of the rabbits. A 
critical size defect of 26 ×  5 ×  3 mm
3 was made in a buccolingual direction on both sides of the 
mandible. The same size porous scaffolds or scaffold/cell constructs were inserted into the defects 
(Figure  10A,B).  Five  rabbits  randomly  selected  from  each  group  were  sacrificed  at  4,  8,  and  
12  weeks  after  implantation,  respectively.  Their  mandibles  were  harvested  and  processed  for  
X-ray detection. 
3.3.8. X-ray Detection 
After sacrifice, lateral radiographs of the mandibles were taken with the mandibles positioned at  
10 cm from the X-ray tube. The X-ray unit (Gendex DEN S-O-MAT, Milano, IL, USA) was set at  
70 kV and 7 mA with a 0.26 s exposure time. 
3.3.9. Statistical Analysis 
All  data  were  expressed  as  means  ±  SD  (standard  deviation).  One-way  analysis  of  variance 
(ANOVA)  and  Student’s  t  test  were  conducted  to  compare  differences  between  groups  using  
SPSS 14.0 [34]. Differences were considered to be significant when p < 0.05 or p < 0.01. 
4. Conclusions 
PLCL/Col/nHA vascular stents were successfully prepared by electrospinning and the surface of the 
stents modified by PEI, heparin and chitosan. The stents can be used in tissue engineering as small 
vessel  stents  with  good  mechanical,  biological  and  anticoagulant  properties.  In  addition,  new  
nano-composite  PLGA/PCL/nHA  scaffolds  loaded  with  the  PLCL/Col/nHA  vascular  stents  were 
prepared by a thermoforming-particle leaching method. These can serve as ideal scaffolds for tissue 
engineering  with  good  mechanical,  biological  and  osteogenic  properties  for  related  experimental 
studies of bone tissue engineering both in vivo and in vitro. 
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